Abstract 778
Case Summary
This case report is a 64-year-old male presented with progressive right hemiparesis 2 months. CT brain shown left frontal mass with perilesional edema size 15*11 cm. He underwent to craniotomy and tumor removal. Histopathology of brain and dura tissues reported anaplastic meningioma (WHO grade III) with mitotic activity 20/10 HPF. In October 2016, he presented with masses at the scalp and 4 months later he had right hemiparesis and right facial palsy. MRI brain shown progressive left frontal lobe meningioma multiple scalp mass. In February 2017, the patient underwent for left frontal craniotomy with tumor removal. Pathological reported anaplastic (WHO grade III) with mitotic activity 20/10 HPF. CT chest shown multiple pulmonary nodules both lungs, enlarge hypodense node at a periaortic area and new develop right hypovascular nodule at the right kidney. Then he undergone the bronchoscopy but histopathologic had reported the presence of lung tissue with mild inflammation. That time he had received tamoxifen 20 mg once daily. Then he did Intensity-modulated radiotherapy (IMRT) at brain and scalp lesion. A tamoxifen was started in February 2017 until May 2017. Followed Magnetic resonance imaging (MRI) shown progressive of the residual at left frontotemporal regions with left frontal lobe invasion. CT chest was reported increased pleural effusion at right lung and increased both multiple solids nodules and mediastinal nodes. In June 2017, Pleural effusion had rapid increase in volume. After there he had been done pleuroscopy for pleural biopsy and talc pleurodesis. Histopathological of pleura shown metastatic meningioma. Immunohistochemistry shown positive EMA and D2-40 and negative for AE1/AE3, TTF-1, P40, calretinin, WT1, and CAM5.2. Then the patient had been palliative care until passed
Anaplastic meningioma is uncommon and poor prognosis tumor. It found about 2-3 % of all meningiomas. The tumor is aggressive and rapid growing and a higher rate of recurrence. The treatment of choice is complete surgery followed by radiotherapy. There is no standard effective of chemotherapy. Some evidence suggests hormonal therapy which use tamoxifen to treat inoperable meningioma. In this patient was received tamoxifen but poor response rate and finally tumor has a progression
Editorial acknowledgement
Clinical trial identification
Resources from the same session
780 - The adipocyte suppresses the inhibitory role of hsa_circ_0000190 in the metastasis of breast cancer cells
Presenter: Xiu Chen
Session: Poster display - Cocktail
Resources:
Abstract
782 - CircASS1 suppressed the invasion and metastasis ability of breast cancer cell line by targeting gene ASS1 and harboring miR-4443
Presenter: Junchen Hou
Session: Poster display - Cocktail
Resources:
Abstract
916 - Ex-vivo drug sensitivity of primary breast cancer stems cell populations to potentiate therapeutic strategy for treatment resistant breast cancer
Presenter: Sourav Nandi
Session: Poster display - Cocktail
Resources:
Abstract
928 - Molecular Tumor Board (MTB): development of clinical pathways for precision medicine. Experiences of Center for Breast cancer at National cancer center, Korea
Presenter: In Hae Park
Session: Poster display - Cocktail
Resources:
Abstract
1274 - MicroRNA based immune response signature identifies poor prognostic subgroup within ER negative breast cancers
Presenter: Savitha Rajarajan
Session: Poster display - Cocktail
Resources:
Abstract
165 - The clinical efficacy of apatinib combined with Xeloda in advanced triple negative breast cancer
Presenter: YiHui Li
Session: Poster display - Cocktail
Resources:
Abstract
561 - Quality of life and psychosocial needs of metastatic breast cancer patients
Presenter: Tahir Mehmood
Session: Poster display - Cocktail
Resources:
Abstract
697 - TC-1 mediate the TBC1D3 oncogene induced migration of MCF-7 breast cancer cells
Presenter: Yong Shen
Session: Poster display - Cocktail
Resources:
Abstract
784 - RelB facilitates cell migration and invasion in breast cancer via MMP1 upregulation
Presenter: Mei Wang
Session: Poster display - Cocktail
Resources:
Abstract
921 - Re-challenging eribulin in patients with ER+HER2- metastatic breast cancer: A single-institution experience
Presenter: Junichiro Watanabe
Session: Poster display - Cocktail
Resources:
Abstract